XRTX: XORTX Therapeutics Inc Company Value to Net Income

XORTX Corp - graphic logo of issuer XRTX

The R&D strategy of XORTX Therapeutics Inc. (XRTX) focuses on developing hypouricemic agents to combat renal pathologies, where trials of key molecules are progressing steadily. The development of drugs for polycystic kidney disease is being conducted in collaboration with specialized medical centers. This chart of the stock price, featuring the -0.60 indicator, complements the brand profile, which is valued by nephrologists for the reliability and safety of the proposed therapeutic solutions.

XORTX Therapeutics (XRTX) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for XORTX Corp (XRTX)

- price and consensus price forecast:
Comprehensive company analysis:XORTX Therapeutics XRTX
Signature product of XORTX

Conservative capital demands maximum transparency of business value relative to its earnings. This ratio measures the market price of a single share divided by net income, determining the investment payback period. For XORTX Therapeutics Inc. (XRTX), this metric reflects the capitalization of the potential of drugs against renal degradation. Analysis of the issuer's P/E chart allows for the identification of asset overvaluation. The indicator's trend serves as a tool for portfolio stress testing.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|P/E Multiple AKTX|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd)|Price to Earnings Ratio Q32 Bio Inc. QTTB|GOVX - Price to Earnings Ratio|EDSA - Price to Earnings Ratio|Market Cap to Earnings iBio|CARM: P/E Multiple|Market Cap to Net Income XTLB (XTL Biopharmaceuticals, Ltd.)|Price to Earnings Ratio boltbio.com|P/E Multiple HCW Biologics|P/E Multiple APVO|AIM - Market Cap to Earnings|P/E Multiple ADTX (Aditxt Inc.)|Business Payback Period GRI Bio, Inc. (GRI)|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple